Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

3.495 -0.035 (-0.99%)

Streaming Delayed Price Updated: 1:55 PM EDT, Jun 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	471,130
Open	3.500
Bid (Size)	3.490 (1,100)
Ask (Size)	3.500 (1,300)
Prev. Close	3.530
Today's Range	3.435 - 3.505
52wk Range	1.350 - 4.600
Shares Outstanding	22,506,956
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

May 20, 2026

Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+115.7%	+115.7%
1 Month	-7.5%	-7.5%
3 Month	+39.8%	+39.8%
6 Month	+136.1%	+136.1%
1 Year	+14.2%	+14.2%

More News

Eledon Pharmaceuticals Inc (NASDAQ:ELDN) Reports Narrower Q4 Loss and Positive Clinical Data for Tegoprubart ↗

March 19, 2026

Via Chartmill

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

March 19, 2026

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine

March 16, 2026

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

March 10, 2026

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

March 04, 2026

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 05, 2026

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

January 23, 2026

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

January 08, 2026

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

December 01, 2025

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Tuesday's after hours session: top gainers and losers ↗

November 18, 2025

Via Chartmill

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

November 18, 2025

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

November 14, 2025

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 14, 2025

Via Benzinga

Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering

November 12, 2025

Via MarketMinute

Top movers in Wednesday's pre-market session ↗

November 12, 2025

Via Chartmill

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 12, 2025

Via Benzinga

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

November 11, 2025

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern

November 10, 2025

Via MarketMinute

What's going on in today's after hours session ↗

November 07, 2025

Via Chartmill

What's going on in today's session ↗

November 07, 2025

Via Chartmill

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study ↗

November 07, 2025

Via Benzinga

Dow Dips Over 200 Points; Fluor Shares Slide After Q3 Results ↗

November 07, 2025

Via Benzinga

Frequently Asked Questions

Is Eledon Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Eledon Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Eledon Pharmaceuticals, Inc. - Common Stock trade on?

Eledon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock is ELDN on the Nasdaq Stock Market

What is the current price of Eledon Pharmaceuticals, Inc. - Common Stock?

The current price of Eledon Pharmaceuticals, Inc. - Common Stock is 3.495

When was Eledon Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Eledon Pharmaceuticals, Inc. - Common Stock was at 06/03/26 01:55 PM ET

What is the market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock is 78.66M

How many shares of Eledon Pharmaceuticals, Inc. - Common Stock are outstanding?

Eledon Pharmaceuticals, Inc. - Common Stock has 79M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.